Non-selective beta-blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real-world study,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Non-selective beta-blocker is associated with reduced mortality in critically ill patients with cirrhosis: A real-world study
Alimentary Pharmacology & Therapeutics ( IF 6.6 ) Pub Date : 2024-08-01 , DOI: 10.1111/apt.18188
Rahul Kumar _{1,

2,

3} , Su Lin _{1,

4} , Gautam Mehta ₁ , Monica D. Mesquita _{1,

5} , Joana A. F. Calvao _{1,

5} , M. Faisal Sheikh ₁ , Banwari Agarwal _{5,

6} , R. P. Mookerjee _{1,

7} , Rajiv Jalan ₁

Affiliation

Apart from direct portal pressure reduction, non-selective beta-blockers (NSBB) modulate inflammatory response, which could be beneficial in patients with acute decompensation (AD). We therefore aimed to evaluate the effect of NSBB on 28-day mortality and markers of systemic inflammation in a propensity score-matched (PSM) cohort of AD patients requiring intensive care unit (ICU) admission.

中文翻译：

非选择性β受体阻滞剂与肝硬化危重患者死亡率降低相关：一项真实世界研究

除了直接降低门静脉压力外，非选择性β受体阻滞剂（NSBB）还可调节炎症反应，这对急性失代偿（AD）患者可能有益。因此，我们的目的是评估 NSBB 对需要入住重症监护病房 (ICU) 的 AD 患者倾向评分匹配 (PSM) 队列中 28 天死亡率和全身炎症标志物的影响。

更新日期：2024-08-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>